Pharma executives join board of Innovative Medicines Initiative
This article was originally published in Scrip
Executive Summary
Roch Doliveux, CEO of UCB, has joined the governing board of the Innovative Medicines Initiative (IMI) Joint Undertaking, a public-private partnership between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Also joining the board are Salah-Dine Chibout, global head of investigative toxicology at Novartis, and David Roblin, senior vice-president and head of research at Pfizer's Sandwich laboratories in the UK. IMI aims to foster collaboration in biopharmaceutical R&D between academia, industry, regulatory agencies, patient organisations and small and medium-sized enterprises. It is already sponsoring 15 ongoing research projects and nine further grants will be awarded this summer. Its total budget for 2008-17 is €2 billion. It is chaired by Carlo Incerti, head of R&D Europe at Genzyme.